Capstone Therapeutics (CAPS) to Release Quarterly Earnings on Wednesday

Capstone Therapeutics (NASDAQ:CAPS) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Capstone Therapeutics to announce earnings of $0.12 per share and revenue of $20.3850 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 8:00 AM ET.

Capstone Therapeutics (NASDAQ:CAPS) last announced its quarterly earnings results on Wednesday, May 20th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Capstone Therapeutics had a negative net margin of 41.26% and a negative return on equity of 114.15%. The firm had revenue of $12.64 million during the quarter, compared to the consensus estimate of $10.80 million.

Capstone Therapeutics Stock Performance

NASDAQ:CAPS opened at $0.28 on Monday. The company has a market capitalization of $4.29 million, a P/E ratio of -0.08 and a beta of -1.52. The stock’s 50 day moving average price is $0.27 and its 200 day moving average price is $0.45. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.29 and a current ratio of 0.95. Capstone Therapeutics has a 52 week low of $0.23 and a 52 week high of $2.07.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Capstone Therapeutics stock. DRW Securities LLC bought a new position in Capstone Therapeutics Corp. (NASDAQ:CAPS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned about 1.51% of Capstone Therapeutics as of its most recent filing with the Securities and Exchange Commission. 2.55% of the stock is currently owned by institutional investors and hedge funds.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.